U.S. Mrna Therapeutics Contract Development & Manufacturing Market Size & Outlook
U.S. mrna therapeutics contract development & manufacturing market, 2021-2030 (US$M)
Related Markets
U.S. mrna therapeutics contract development & manufacturing market highlights
- The U.S. mrna therapeutics contract development & manufacturing market generated a revenue of USD 1,327.6 million in 2023 and is expected to reach USD 2,802.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 11.3% from 2024 to 2030.
- In terms of segment, infectious diseases was the largest revenue generating indication in 2023.
- Infectious Diseases is the most lucrative indication segment registering the fastest growth during the forecast period.
Mrna therapeutics contract development & manufacturing market data book summary
| Market revenue in 2023 | USD 1,327.6 million |
| Market revenue in 2030 | USD 2,802.8 million |
| Growth rate | 11.3% (CAGR from 2023 to 2030) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Infectious Diseases |
| Historical data | 2021 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Infectious Diseases |
| Key market players worldwide | Danaher Corp, Kaneka Corp, TriLink BioTechnologies, Apex Biotechnology, BioNTech SE ADR, Lonza Group Ltd, Nunn’s Home Medical Equipment, EQT Corp, Catalent Inc, Samsung Electronics Co Ltd, Biomay AG, Indication, eTheRNA immunotherapies, BioCina |
Other key industry trends
- In terms of revenue, U.S. accounted for 32.0% of the global mrna therapeutics contract development & manufacturing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. mrna therapeutics contract development & manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 2,802.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
MRNA Therapeutics Contract Development & Manufacturing Market Scope
MRNA Therapeutics Contract Development & Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. mrna therapeutics contract development & manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics contract development & manufacturing market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the U.S. mrna therapeutics contract development & manufacturing market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
The U.S. accounts for the highest share of North America mRNA therapeutics contract development & manufacturing organization (CDMO) market as many pharmaceutical and life sciences companies are present in this country.
Growing interest in clinical trials and the benefits of live biotherapeutics in treating rare diseases are driving the development of new & novel drugs. Moreover, a wellestablished regulatory framework provides new opportunities for companies to develop and manufacture products with wide applications & target population and improved knowledge of the importance of mRNA in terms of therapeutics.
In addition, in recent years, rapid growth has been observed in the mRNA therapeutic landscape, with several candidates in clinical studies. For instance, in December 2022, Moderna & Merck announced the phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, a personalized mRNA cancer vaccine with KEYTRUDA combination.
Reasons to subscribe to U.S. mrna therapeutics contract development & manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. mrna therapeutics contract development & manufacturing market databook
-
Our clientele includes a mix of mrna therapeutics contract development & manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. mrna therapeutics contract development & manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. mrna therapeutics contract development & manufacturing market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. mrna therapeutics contract development & manufacturing market size, by indication, 2021-2030 (US$M)
U.S. MRNA Therapeutics Contract Development & Manufacturing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
